vs
MESA LABORATORIES INC（MLAB）とSafehold Inc.（SAFE）の財務データ比較。上の社名をクリックして会社を切り替えられます
Safehold Inc.の直近四半期売上が大きい（$97.9M vs $65.1M、MESA LABORATORIES INCの約1.5倍）。Safehold Inc.の純利益率が高く（28.5% vs 5.6%、差は22.9%）。Safehold Inc.の前年同期比売上増加率が高い（6.5% vs 3.6%）。過去8四半期でMESA LABORATORIES INCの売上複合成長率が高い（5.1% vs 2.5%）
メサラボラトリーズ社は、品質管理、校正、モニタリング向け専門機器及び関連サービスの開発・製造・販売を事業としています。医療、製薬、食品飲料、産業衛生、環境試験分野を中心に、世界中の顧客の規制遵守と運用安全のニーズに応えています。
SAFE投資有限公司は中国香港に拠点を置く中国のソブリン・ウェルス・ファンドです。主に主権富に関わる投資運用業務を担当し、香港の国際金融センターとしての優位性を活かして関連投資事業を展開しています。
MLAB vs SAFE — 直接比較
売上が大きい
SAFE
1.5倍大きい
$65.1M
売上成長率が高い
SAFE
+2.9%の差
3.6%
純利益率が高い
SAFE
純利益率が22.9%高い
5.6%
2年売上CAGRが高い
MLAB
2年複合成長率
2.5%
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $65.1M | $97.9M |
| 純利益 | $3.6M | $27.9M |
| 粗利率 | 64.2% | 98.6% |
| 営業利益率 | 12.2% | 27.4% |
| 純利益率 | 5.6% | 28.5% |
| 売上前年比 | 3.6% | 6.5% |
| 純利益前年比 | 316.6% | 7.1% |
| EPS（希薄化後） | $0.65 | $0.38 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上MLABSAFE
| Q4 25 | $65.1M | $97.9M | ||
| Q3 25 | $60.7M | $96.2M | ||
| Q2 25 | $59.5M | $93.8M | ||
| Q1 25 | $62.1M | $97.7M | ||
| Q4 24 | $62.8M | $91.9M | ||
| Q3 24 | $57.8M | $90.7M | ||
| Q2 24 | $58.2M | $89.9M | ||
| Q1 24 | $58.9M | $93.2M |
純利益MLABSAFE
| Q4 25 | $3.6M | $27.9M | ||
| Q3 25 | $2.5M | $29.3M | ||
| Q2 25 | $4.7M | $27.9M | ||
| Q1 25 | $-7.1M | $29.4M | ||
| Q4 24 | $-1.7M | $26.0M | ||
| Q3 24 | $3.4M | $19.3M | ||
| Q2 24 | $3.4M | $29.7M | ||
| Q1 24 | $-254.6M | $30.7M |
粗利率MLABSAFE
| Q4 25 | 64.2% | 98.6% | ||
| Q3 25 | 61.5% | 98.5% | ||
| Q2 25 | 62.0% | 99.1% | ||
| Q1 25 | 61.8% | 98.8% | ||
| Q4 24 | 63.3% | 98.8% | ||
| Q3 24 | 61.3% | 98.8% | ||
| Q2 24 | 64.0% | 98.8% | ||
| Q1 24 | 62.1% | 98.8% |
営業利益率MLABSAFE
| Q4 25 | 12.2% | 27.4% | ||
| Q3 25 | 7.8% | 25.9% | ||
| Q2 25 | 5.1% | 25.5% | ||
| Q1 25 | 2.4% | 25.9% | ||
| Q4 24 | 9.2% | 24.6% | ||
| Q3 24 | 6.1% | 17.5% | ||
| Q2 24 | 9.6% | 26.7% | ||
| Q1 24 | -460.6% | 26.4% |
純利益率MLABSAFE
| Q4 25 | 5.6% | 28.5% | ||
| Q3 25 | 4.1% | 30.5% | ||
| Q2 25 | 8.0% | 29.8% | ||
| Q1 25 | -11.4% | 30.1% | ||
| Q4 24 | -2.7% | 28.3% | ||
| Q3 24 | 5.9% | 21.3% | ||
| Q2 24 | 5.8% | 33.0% | ||
| Q1 24 | -432.2% | 33.0% |
EPS（希薄化後）MLABSAFE
| Q4 25 | $0.65 | $0.38 | ||
| Q3 25 | $0.45 | $0.41 | ||
| Q2 25 | $0.85 | $0.39 | ||
| Q1 25 | $-1.30 | $0.41 | ||
| Q4 24 | $-0.31 | $0.36 | ||
| Q3 24 | $0.63 | $0.27 | ||
| Q2 24 | $0.62 | $0.42 | ||
| Q1 24 | $-47.26 | $0.43 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $29.0M | $21.7M |
| 総負債低いほど良い | $68.4M | $4.6B |
| 株主資本純資産 | $186.7M | $2.4B |
| 総資産 | $434.8M | $7.2B |
| 負債/資本比率低いほどレバレッジが低い | 0.37× | 1.90× |
8四半期トレンド — 暦四半期で整列
現金・短期投資MLABSAFE
| Q4 25 | $29.0M | $21.7M | ||
| Q3 25 | $20.4M | $12.1M | ||
| Q2 25 | $21.3M | $13.9M | ||
| Q1 25 | $27.3M | $17.3M | ||
| Q4 24 | $27.3M | $8.3M | ||
| Q3 24 | $24.3M | $15.6M | ||
| Q2 24 | $28.5M | $13.4M | ||
| Q1 24 | $28.2M | $11.3M |
総負債MLABSAFE
| Q4 25 | $68.4M | $4.6B | ||
| Q3 25 | $69.4M | $4.5B | ||
| Q2 25 | $70.3M | $4.4B | ||
| Q1 25 | $71.3M | $4.3B | ||
| Q4 24 | $72.2M | $4.3B | ||
| Q3 24 | $73.1M | $4.3B | ||
| Q2 24 | $74.1M | $4.2B | ||
| Q1 24 | — | $4.1B |
株主資本MLABSAFE
| Q4 25 | $186.7M | $2.4B | ||
| Q3 25 | $178.5M | $2.4B | ||
| Q2 25 | $172.5M | $2.4B | ||
| Q1 25 | $159.8M | $2.4B | ||
| Q4 24 | $155.2M | $2.3B | ||
| Q3 24 | $161.5M | $2.3B | ||
| Q2 24 | $150.7M | $2.3B | ||
| Q1 24 | $145.4M | $2.3B |
総資産MLABSAFE
| Q4 25 | $434.8M | $7.2B | ||
| Q3 25 | $430.4M | $7.1B | ||
| Q2 25 | $435.7M | $7.1B | ||
| Q1 25 | $433.3M | $6.9B | ||
| Q4 24 | $433.3M | $6.9B | ||
| Q3 24 | $454.1M | $6.8B | ||
| Q2 24 | $440.4M | $6.8B | ||
| Q1 24 | $446.8M | $6.7B |
負債/資本比率MLABSAFE
| Q4 25 | 0.37× | 1.90× | ||
| Q3 25 | 0.39× | 1.89× | ||
| Q2 25 | 0.41× | 1.87× | ||
| Q1 25 | 0.45× | 1.85× | ||
| Q4 24 | 0.47× | 1.84× | ||
| Q3 24 | 0.45× | 1.88× | ||
| Q2 24 | 0.49× | 1.81× | ||
| Q1 24 | — | 1.81× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $18.8M | $47.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $18.0M | — |
| FCFマージンFCF / 売上 | 27.7% | — |
| 設備投資強度設備投資 / 売上 | 1.1% | — |
| キャッシュ転換率営業CF / 純利益 | 5.17× | 1.72× |
| 直近12ヶ月FCF直近4四半期 | $37.9M | — |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローMLABSAFE
| Q4 25 | $18.8M | $47.8M | ||
| Q3 25 | $8.2M | $-1.4M | ||
| Q2 25 | $1.9M | $28.0M | ||
| Q1 25 | $12.7M | $8.9M | ||
| Q4 24 | $18.1M | $37.9M | ||
| Q3 24 | $5.3M | $8.3M | ||
| Q2 24 | $10.7M | $24.8M | ||
| Q1 24 | $12.9M | $-3.1M |
フリーキャッシュフローMLABSAFE
| Q4 25 | $18.0M | — | ||
| Q3 25 | $7.1M | — | ||
| Q2 25 | $884.0K | — | ||
| Q1 25 | $11.9M | — | ||
| Q4 24 | $17.3M | — | ||
| Q3 24 | $3.5M | — | ||
| Q2 24 | $9.9M | — | ||
| Q1 24 | $12.3M | — |
FCFマージンMLABSAFE
| Q4 25 | 27.7% | — | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 19.2% | — | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 6.0% | — | ||
| Q2 24 | 16.9% | — | ||
| Q1 24 | 21.0% | — |
設備投資強度MLABSAFE
| Q4 25 | 1.1% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 0.9% | — |
キャッシュ転換率MLABSAFE
| Q4 25 | 5.17× | 1.72× | ||
| Q3 25 | 3.32× | -0.05× | ||
| Q2 25 | 0.40× | 1.00× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | 1.54× | 0.43× | ||
| Q2 24 | 3.17× | 0.83× | ||
| Q1 24 | — | -0.10× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
SAFE
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $60.3M | 62% |
| Other | $33.7M | 34% |
| Stabilized Properties | $3.8M | 4% |
